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Abstract
Objective. To describe 12-month treatment patterns
and outcomes for patients starting a new medication
for fibromyalgia in routine clinical practice.
Design and Outcome Measures. Data from 1,700
patients were collected at baseline and 1, 3, 6, and
12 months. Repeated measures and Poisson regres-
sion models controlling for demographic, clinical,
and baseline outcomes were used to assess
changes in health outcomes (Brief Pain Inventory
severity and interference, Sheehan Disability Scale,
Fibromyalgia Impact Questionnaire), satisfaction,
and economic factors for patients who initiated on
pregabalin (214, 12.6%), duloxetine (264, 15.5%), mil-
nacipran (134, 7.9%), or tricyclic antidepressants
(66, 3.9%). Sensitivity analyses were run using
propensity-matched cohorts.
Results. Patients started on 145 unique drugs for
fibromyalgia, and over 75% of patients took two or
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more medications concurrently for fibromyalgia at
each time point assessed. Overall, patients showed
improvement on the four health outcomes, with few
differences across medication cohorts. At baseline,
patients reported annual averages of 20.3 visits for
outpatient care, 27.7 missed days of work, and 32.6
days of care by an unpaid caregiver. The duloxetine
and milnacipran (vs pregabalin or tricyclic antide-
pressant) cohorts had fewer outpatient visits during
the 12-month study. Patients reported satisfaction
with overall treatment and their fibromyalgia medi-
cation (46.0% and 42.8%, respectively).
Conclusions. In this real-world setting, patients
with fibromyalgia reported modest improvements,
high resource, and medication use, and were satis-
fied with the care they received. Cohort differences
were difficult to discern because of the high rates of
drug discontinuation and concomitant medication
use over the 12-month study period.
Key Words. Fibromyalgia; Treatment; Observa-
tional; Longitudinal; Pharmacotherapy; Outcomes
Introduction
Fibromyalgia (FM) is a painful chronic condition associated
with high levels of long-term social and economic burden
[1]. Patients experience a wide range of symptoms with
varying intensities that can wax and wane over time [2].
Only one study was found to measure health outcomes
over time (without assessment of treatment) in large clini-
cal practice settings [3]. In that study, 1,555 patients iden-
tified through the National Data Bank for Rheumatic
Diseases were surveyed in 6-month intervals for a mean
duration of 4 years and were found to have generally high
levels of symptoms and distress over time, with modest
improvement noted over the period of observation.
Because of the chronic nature of FM, patients experience
long-term illness-related burdens, including reduced daily
functioning and interference with work (including absen-
teeism and productivity loss while at work), as well as
disability assistance claims and economic difficulties [4,5].
In one 6-month study of 91 working women with FM, 25%
received disability assistance or retired because of FM,
and over 50% missed some work because of the condi-
tion (approximately 4 weeks annually) [4]. Patients with FM
may experience substantial losses in quality of life [6] while
incurring great costs for health care services [5].
Poor economic outcomes have been associated with the
presence of symptoms common in FM, including chronic
pain, depressive symptoms, sleep disturbances, fatigue,
back pain, and anxiety [7–12]. Further, family members
and caregivers of patients with FM experience caregiver-
related burdens as well as economic hardships [13].
Among the goals of treatment for FM are pain reduction,
restoration of physical function, and reduction in the utili-
zation of expensive health care resources [14]. Deciding
on the appropriate treatment may be complicated by the
overlap of FM with symptoms of other health conditions,
such as other pain or mood disorders, sleep disturbances,
and fatigue [15–17]. It is believed that medications target-
ing more than one symptomatic domain (i.e., those with
unique underlying biochemical and neurophysiologic
abnormalities) may allow for more successful individual-
ization of therapy [14].
Currently, there are three US Food and Drug Administra-
tion (FDA)–approved medications for the management of
FM: pregabalin, which is an a-2-delta modulator, and the
serotonin and norepinephrine reuptake inhibitors (SNRIs)
duloxetine and milnacipran. FDA approvals for the man-
agement of FM were granted in June 2007 for pregabalin,
June 2008 for duloxetine, and January 2009 for milnacip-
ran. In addition, various other drug classes, such as tricy-
clic antidepressants (TCAs), are used off-label to treat FM
and are often recommended as first-line therapy [18–20].
Most research examining medication treatment patterns
for patients with FM have used retrospective insurance
claims data [21–25]. These studies report extensive use of
prescription medications and other health care resources
in patients with FM. Earlier work identified that total direct
and indirect costs for claimants with FM were twice the
total cost of overall claimants, with the indirect costs three
times higher [21]. However, only 6% of these costs were
attributable to FM-specific claims [21]. Recent studies
highlight that the choice of treatment may be influenced by
patient demographics or the presence of select comor-
bidities [26]. For example, patients with FM who were
prescribed duloxetine vs other medications were more
likely to have a history of rheumatoid arthritis or sleep
disorders [26]. The most effective treatments reported by
self-selected respondents to an Internet survey were rest,
heat, pain medications, antidepressants, and hypnotics
[27]. The medications perceived to be the most effective
were hydrocodone preparations, alprazolam, oxycodone
preparations, zolpidem, cyclobenzaprine, and clon-
azepam [27]. The results of this survey and claims data
guided the development of the current study, ensuring the
full representation of specific medications, symptoms, and
comorbid conditions identified for study.
To our knowledge, no study has addressed the long-term
treatment patterns and effect of various therapies on out-
comes for patients receiving care for FM in actual clinical
practice [28]. Randomized clinical trials may not be repre-
sentative of patients in general practice, where comorbid
conditions and concomitantmedications are common [29].
Data from insurance claims cannot determine clinical out-
comes associated with medication use, nor can claims
distinguish the indication for use when multiple conditions
are present.
This observational study, which we identified as the
REFLECTIONS (Real World Examination of Fibromyal-
gia: Longitudinal Evaluation of Costs and Treatments)
study, was designed to prospectively evaluate long-term
treatment patterns, health outcomes, and economic
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outcomes in actual clinical practice among patients who
were newly prescribed a medication for FM and followed
for 12 months. Baseline findings from REFLECTIONS pre-
viously reported high levels of burden of illness and much
variability in treatment patterns for patients with FM [28].
At baseline, most patients experienced moderate to
severe symptoms of pain, disability, insomnia, depression,
and anxiety. Almost all patients had multiple visits to out-
patient facilities and almost half missed work due to FM.
Caregivers also have work limitations due to the patient’s
FM. On average, patients had experienced FM for 5 years.
Patients were taking a variety of medications and alterna-
tive or complementary treatment modalities. Multiple treat-
ment approaches were observed, with physicians
prescribing 182 different medications to treat patients with
FM. The majority of patients (78%) was taking more than
one medication for FM and was also prescribed non-
pharmacologic interventions (60.5%) at study entry. The
treatments with the most evidence to support their use
were not always the most frequently chosen. Common
medications included the FDA-approved medications
duloxetine (26.8%), pregabalin (24.5%), and milnacipran
(8.9%). Nonsteroidal anti-inflammatory drugs (26.6%),
opioids (24.2%), and benzodiazepines (15.2%) were also
among the more frequently used medications despite little
or inconclusive evidence to support the efficacy of these
medications to treat FM.
Treatment selection of branded medications vs all other
drugs was most strongly associated with physician spe-
cialty, insurance type, and medication history and not
significantly related to current medication patterns or
severity of pain and other FM-related symptoms [28]. In
multivariate models, duloxetine initiators were more likely
to have private insurance; sustain greater reductions in
activities; have physicians who were female, rheumatolo-
gists, or other specialists; and take more FM medications
[28]. They were less likely to be using opioids or nonste-
roidal anti-inflammatory drugs (NSAIDs) [28]. Pregabalin
initiators were more likely to be <65 years of age, have
“not enough” income, have lower Fibromyalgia Impact
Questionnaire (FIQ) total scores, have physicians who
were younger and rheumatologists [28], and take more
FM medications. They were less likely to be using NSAIDs.
Milnacipran initiators were more likely to have higher body
mass indexes (BMIs), better (lower) scores on cognitive
and physical functioning, more severe insomnia, and phy-
sicians who were rheumatologists or other specialists.
They were less likely to use NSAIDs. “Other” medication
initiators were more likely to be 65 years of age and use
opioids/NSAIDs, were less likely to have physicians who
were males and primary care physicians, and took a lower
mean number of medications.
For this longitudinal assessment of REFLECTIONS, the
objectives were 1) to describe the 12-month treatment
patterns for patients who are “newly prescribed” pharma-
cologic treatments for FM; 2) to examine illness-related
burdens considered key to quality of life patients with FM
[30] including pain severity and interference (Brief Pain
Inventory [BPI]) [31], disability (Sheehan Disability Scale
[SDS]) [32], function (FIQ) [33], and economic factors
associated with work loss and health care resource utili-
zation; and 3) to examine patients’ satisfaction with their
overall medical care and with their medication.
Methods
Study Setting
The study methodology is fully described by Robinson
et al. [28] and summarized here as it pertains to this
report. Study participants were enrolled from 58 health
care settings (including 91 participating physicians) in the
United States and Puerto Rico. Study sites included out-
patient practices of rheumatology (59.3%), primary care
(37.4%), neurology (2.2%), psychiatry (3.3%), pain spe-
cialists (3.3%), physical medicine (2.2%), obstetrics, and
gynecology (1.1%), and osteopathy (1.1%). Sites were
selected on the basis of reported number of patients seen
per month, experience in observational or clinical
research, and whether they received good clinical practice
training prior to being included in the study. The protocol
was approved by either a central or site-specific institu-
tional review board. All patients provided written informed
consent before participating in the study.
Eligible patients were at least 18 years of age, had been
determined to have FM by the enrolling physician, were
under the care of the enrolling physician, were cognitively
able to understand and complete patient self-rated scales
in English or Spanish via telephone interviews, and agreed
to participate in the study for 12 months. Patients also had
to be initiating a “new” treatment for FM, defined as being
naive to the treatment (over the last 6 months), starting a
new therapy to replace a previously used therapy (switch-
ing treatment), or adding a new therapy to their current FM
treatment regimen (augmenting treatment). Study site per-
sonnel and/or their immediate families were excluded from
the study.
Study Design and Measures
This was a prospective 12-month observational study
designed to determine the treatment patterns and health
outcomes (including symptom severity, functionality, and
economic impact) of patients with FM. Measures included
in REFLECTIONS were in part those deemed important for
determining treatment success in other studies by the
Outcome Measures in Rheumatology Clinical Trial fibro-
myalgia steering committee [30]. The domains included
pain, fatigue, global functioning, sleep quality, health-
related quality of life, physical functioning, depression,
anxiety, and dyscognition. All patient care by the enrolling
physician occurred as part of the physician’s routine clini-
cal care. Treatment pattern and treatment initiation or
changes were solely at the discretion of the physician and
the patient. Patients could initiate a “new” pharmacologic
agent at any time in their management cycle for FM.
Data were collected using a physician survey, a patient
visit form, and computer-assisted telephone interviews
1402
Robinson et al.
(CATI). Prior to enrolling patients into the study, the phy-
sician completed a physician survey to identify his or her
demographic and practice characteristics (such as
number of years in practice and specialty) and beliefs and
attitudes about FM. Patients were invited to participate in
the study during a patient visit in which the patient was
prescribed a new pharmacologic treatment for manage-
ment of FM. Unlike previous studies or claims assess-
ments, the REFLECTIONS study used a list of unique
medications that included any treatment that physicians
reported specifically for the treatment of FM. Each medi-
cation reported by the physician was uniformly coded, as
defined using the World Health Organization Drug Dictio-
nary classification for unique medicinal products at the
generic name level [34] (e.g., pregabalin, duloxetine, mil-
nacipran, gabapentin, acetaminophen, amitriptyline, tra-
madol, cyclobenzaprine). For descriptive purposes, drugs
were later categorized using this classification system at
the class (e.g., selective serotonin reuptake inhibitor
[SSRI]) or therapeutic level (e.g., antidepressants). A
patient form was completed at this time to assess patient
demographics, medical history with enriched items on FM
history, baseline treatment patterns, and the physician’s
assessment of the patient. There were no additional
study-specific office visits nor additional input from physi-
cians required for the remainder of the study. All further
data were collected using CATI, in which patients were
asked to respond to various questions regarding their
health status and care. Patients were assessed via 30 to
45-minute telephone interviews in English or Spanish at
baseline, and 1, 3, 6, and 12 months post-baseline. Base-
line interviews were conducted within 14 days of the study
entry. Patients were reimbursed for their time with a $25
gift card for each completed CATI.
Treatment patterns were assessed at each data collec-
tion wave from baseline to 12 months; information col-
lected included 1) type of medications used, 2) the
medication possession ratio (MPR; number of days that
supply of medication was used/number of days in the
12-month study) for selected drugs, 3) number of unique
concurrent medications at each visit, 4) cumulative
number of unique medications over time, and 5) rate of
treatment discontinuation and reasons for discon-
tinuation (multiple responses were allowed, including
“felt better,” “didn’t help,” “adverse events,” “too costly,”
and “other”).
The CATI included the outcome measures of BPI, SDS,
and FIQ, as well as economic outcome measures. The
BPI [31] includes four pain severity items that assess
worst, least, and average pain in the prior week, as well
as pain right now, on a scale from 0 (no pain) to 10 (pain
as bad as you can imagine). These four items were aver-
aged for a mean rating or what is referred to in this
article as a “pain severity average score” (possible range,
0 to 10). In addition, there are 7 BPI interference items
assessing pain-related interference with daily functioning
(e.g., work, physical, and social activity) on a scale from
0 (does not interfere) to 10 (completely interferes); these
items were averaged for a mean rating referred to in this
report as a “pain interference average score” (possible
range, 0 to 10). The SDS [32] assesses disability across
three domains: work/school, social life, and family life/
home responsibilities. The total score ranges from 0 to
30, with higher scores indicating greater disability. The
FIQ [33] assesses physical functioning; number of days
the patient felt well; number of days the patient felt
unable to work due to FM symptoms; and patient
ratings of work difficulty, pain intensity, fatigue, morning
tiredness, stiffness, anxiety, and depression. The FIQ
total score for the version used ranges from 0 to 80, with
a higher score indicating a more negative impact. Eco-
nomic measures included individual patient-rated items
to assess the effect of FM on work or disability status
and health care utilization. Another outcome was the
level of disability due to the patient’s FM, which was
captured using seven variables (in days): family member
missed paid work, had an unpaid caregiver, hired a paid
caregiver, missed work due to FM, stayed in bed, cut
down on activities, and received disability income.
Resource utilization over the 12 months included
number of visits to outpatient facilities overall, emergency
room visits, partial day care, and partial night care. CATI
items also inquired about patients’ satisfaction with their
medical care. Patients were asked to rate “the treatment
of your fibromyalgia overall” as well as “the medication
you were prescribed” from 1 (excellent) to 5 (poor).
Measures that were included in the CATI and were used to
control for differences across patient cohorts included the
Patient Health Questionnaire (PHQ)–15 [35,36], which
captures complaints of common physical symptoms seen
in primary care settings; the Generalized Anxiety Disorder
(GAD)–7 measure [37], which measures severity of GAD;
the PHQ–8 [38,39], which assesses depression severity;
the Insomnia Severity Index (ISI) [40], which measures
individuals’ perceptions of insomnia including symptoms
of sleep and fatigue; and the Massachusetts General Hos-
pital Cognitive and Physical Functioning Questionnaire
(MGH-CPFQ) [41], which measures patients’ cognitive
and physical well-being.
Patients initiated on 145 unique types of medication;
therefore, this study condensed the analysis to only the
three FDA-approved medications and the predomi-
nantly recommended first-line therapy for the treatment
of FM. Thus, the four mutually exclusive medication
cohorts, defined based on medications initiated at base-
line, were: 1) pregabalin, 2) duloxetine, 3) milnacipran,
and 4) TCAs. The specific TCAs included in this analysis
(i.e., amitriptyline, clomipramine, desipramine, dosulepin
hydrochloride, doxepin, imipramine, lofepramine, nortrip-
tyline, and trimipramine) were chosen because they
are considered a first line of therapy in many guidelines
and have been evaluated in the highest number of
clinical studies [19]. Patients who initiated on a combi-
nation of any of these four groups and the remaining
patients who had initiated on other medications were
not included in the medication cohort comparative
analyses but are included in the description of the
overall sample.
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Statistical Analysis
Treatment patterns were summarized using 1) percentage
of patients who used medications from baseline to 12
months, 2) the MPR (number of days that supply of medi-
cation used/number of days in the 12-month study), 3)
number of unique concurrent medications at each visit
and cumulative number of unique medications over time
from baseline to 12 months, and 4) time to treatment
discontinuation estimated by Kaplan–Meier survival analy-
sis, as well as reasons for discontinuation.
Descriptive statistics were used to characterize patients’
demographic and baseline clinical characteristics, physi-
cian characteristics, treatment patterns, baseline outcome
measures, annual use of health care resources recalled by
patients at baseline and use of health care resources
reported by patients post-baseline. Summary statistics
were calculated for the overall sample, for all enrolled
patients (N = 1,700), and for patients in each of the four
cohorts. The four groups were first compared using chi-
square tests for categorical variables and F test (analysis
of variance) for continuous variables. For variables with
significant differences at the P < 0.05 level, a second step,
using pairwise comparisons, was used to further identify
distinctions among the groups.
Repeated-measures regression models for each of the
health outcomes were done to understand the association
of the outcome over time with the initiated medication.
Poisson regression analyses, with a scale parameter to
allow for over-dispersion and length of follow-up as an
offset factor, were done to examine the association of
economic outcomes (including resource utilization) with
the initiated medication. The covariates for the model were
chosen prior to conducting the analysis and included
demographic variables (age, sex, race, region [whether
the patient was receiving treatment in Puerto Rico or the
United States]), baseline clinical variables (BPI pain sever-
ity average score, BPI pain interference, PHQ-8 total score
[used in Poisson regression model for resource utiliza-
tion]); physician specialty, baseline resource utilization vari-
ables (any emergency room visits, any outpatient visits,
any primary care visits [used in repeated measures models
for outcome measures]), baseline opioid use (YES/NO),
and baseline medication status (no treatment in the last 6
months, switching, augmenting).
Because of the nonrandomized nature of these data, mul-
tiple sensitivity analyses were conducted to assess the
robustness of the regression bias adjustment. Sensitivity
analysis included propensity score matching, which is a
commonly used tool in observational research for reduc-
ing bias in analyses involving comparisons between
cohorts. Propensity score matching corrects for cohort
differences in measured covariates, avoids the need to
make assumptions regarding the relationships between
covariates and the outcome variables as is necessary in
regression modeling, and can incorporate more variables
in the propensity adjustment model [42,43]. Propensity
score matched samples were created for three pairwise
cohort comparisons: duloxetine vs pregabalin, duloxetine
vs milnacipran, and duloxetine vs TCA. The variables used
in propensity score logistic regression model included all
the variables listed above plus these additional variables:
demographic variables (BMI; insurance type [none, public
insurance (such as Medicare, Medicaid, Champus),
private insurance (such as Omnicare, Aetna, WellPoint,
Kaiser, etc), or a combination of public and private insur-
ance (such as Medicare and supplemental private insur-
ance)]; socioeconomic status in terms of whether the
patient was comfortable, had just enough to pay the bills,
or did not have enough to pay the bills); baseline clinical
variables (time since first FM symptoms and each total
score for the FIQ, GAD-7, PHQ-15, MGH-CPFQ, ISI,
SDS); physician variables (sex, years of practice); and
baseline resource utilization variables (any physical
therapy visits, any care by unpaid caregiver, days cut
down on activities, use of NSAIDs, and use of tramadol).
For the propensity score matched cohort comparisons, a
propensity score for each patient was estimated using the
above model, then a greedy 1:1 matching algorithm was
used to form propensity score-matched samples. The 1:1
greedy matching algorithm used in this research sequen-
tially matches each patient in the smaller treatment group
(without replacement) to the patient in the other cohort
with whom the absolute differences in the propensity
score are smallest. Standardized differences were com-
puted to confirm appropriate balance between cohorts for
the above covariates, and the propensity matching
process was finalized prior to initiating the outcome analy-
sis. Pairwise cohort differences in each outcome measure
were then examined using repeated-measures models on
the matched samples, with cohort and visit as covariates.
To provide an additional sensitivity analysis that used the
full patient sample, entropy balancing was also utilized.
Entropy balancing is a recently proposed technique that
controls biases due to measured baseline covariates
in observational research comparisons [44]. Similar to
weighting by the inverse of the propensity score, this
approach finds the weight for each patient that leads to
balance between cohorts for the baseline covariates. It
potentially improves on propensity score methods by
directly balancing the covariates such that the means
and the variances of all baseline covariates will be
similar between any number of cohorts. Propensity score
matching is designed for two cohorts and simply
matches on the propensity score, which does not guar-
antee that each matched pair has similar baseline values
for each covariate.
Results
Participant Baseline Characteristics
A total of 2,115 patients were recruited into the study, and
1,700 were successfully enrolled into the study. Of the
baseline patients, 1,205 (70.9%) completed the 12-month
assessment, and 1,073 (63.1%) completed all of the
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assessments; Figure 1 shows the number of patients who
completed the CATI at each assessment.
Participants (N = 1,700) were mostly female (94.6%) and
White (82.9%). Mean (standard deviation [SD]) age was
50.4 (11.9) years, duration of FM diagnosis was 5.6 (6.3)
years, BPI severity was 5.5 (1.8), and BPI interference was
6.1 (2.2). Descriptive baseline information on the overall
sample is fully described by Robinson et al. [28]. Patients
who were not successfully enrolled in the study due to a
missed telephone interview at baseline (n = 316) were
younger than those who enrolled (n = 1,700) (mean age
46.8 vs 50.4 years, P < 0.001); no differences were noted
in sex, race, region, BMI, years since first FM symptom, or
baseline medication status. Patients who completed the
study (N = 1,205) were compared with those who did not
complete the study (N = 495); those who completed the
study were older (mean age 51.5 vs 47.8 years,
P < 0.001) and had experienced FM symptoms for a
longer mean period of time (10.5 vs 8.7 years, P < 0.001);
in addition, a greater percentage were using NSAID medi-
cation at baseline (28.7% vs 22.0%, P = 0.005). No other
statistically significant (P  0.005) differences emerged.
Table 1 contains the demographic and baseline charac-
teristics of patients in each of the four medication cohorts.
Of the overall sample (N = 1,700), 678 patients were
divided into each of the following four cohorts based on
the type of drug initiated at baseline: pregabalin (214/
1,700, 12.6%), duloxetine (264/1,700, 15.5%), milnacip-
ran (134/1,700, 7.9%), and TCAs (66/1,700, 3.9%). Six
patients were initiated on a combination of duloxetine,
milnacipran, pregabalin, or TCA and were excluded from
the four cohorts. Statistical evaluation of baseline charac-
teristics among these cohorts revealed overall significant
differences between the groups in the following variables:
race, region, medication status, physician gender, number
of years physician was in practice, and physician specialty.
Most patients in the pregabalin, duloxetine, milnacipran,
and TCA cohorts enrolled into the study in the United
States (94.9%, 87.9%, 97.0%, and 95.5%, respectively).
Overall, the physicians in this study had been in practice
Total
N = 2,115
Entry criteria not met 67 (3.2%)
Screen Failure, N (%)
Missed baseline interview
Refused
316 (15.4%)
32 (1.6%)
Discontinued, N (%)
Eligible Participants
N = 2,048
Enrolled, n/N (%)
1,700/2,115 (83%)
Baseline
N = 1,700
1-Month Participants
1,548/1,700 (91.1%)
3-Month Participants
1,430/1,700 (84.1%)
6-Month Participants
1,344/1,700 (79.1%)
12-Month Participants
1,205/1,700 (70.9%)
Figure 1 REFLECTIONS study
enrollment and disposition.
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an average of 16 (SD = 8.8) years, and most were male
(84.7%) and identified their specialty as rheumatology
(66.5%). Pairwise comparisons between the four medica-
tion cohorts revealed differences in several variables
including patient characteristics (race, region, medication
status) and physician characteristics (gender, years in
practice, specialty) (Table 1).
Longitudinal Treatment Patterns
Patients in the overall sample took prescription medica-
tions for fibromyalgia 98.6% of the days during the
12-month study. The percentage of days during the
12-month study that patients in the overall sample were
taking one, two, three, four, or at least five medications
was 20.9%, 26.3%, 24.1%, 16.6%, and 10.7%, respec-
tively. Over three fourths of patients were taking two or
more medications at each time interval assessed (77.8%
at baseline, 75.3% at 1 month, 79.5% at 3 months, 78.4%
at 6 months, and 78.9% at 12 months). Similar mean (SD)
cumulative number of medications for FM used by
patients in each of the medication cohorts who completed
all study visits over 12 months were found: pregabalin, 5.0
(2.0); duloxetine, 4.9 (2.0); milnacipran, 5.3 (1.7); and TCA,
4.7 (1.7) (pairwise comparison P > 0.05).
Because multiple medications were used over the 12
months, the data shown in Table 2 for each cohort are the
percentage of medication use (among the 12 most
common types) any time during the study and the mean
length of time for each of these drugs using the MPR
[45,46]. Categories of opioid and NSAID use were high
among the selected medication cohorts with 36.5%
(n = 621) and 36.6% (n = 622) of the overall sample,
respectively, using these medications any time during the
12 months. Use of opioids in each medication cohort
included pregabalin (n = 69), 32.2%; duloxetine (N = 78),
29.5%; milnacipran (N = 62), 46.3%; and TCA (N = 21),
31.8%. Of the overall sample, 411 (24.2%) patients took
any form of gabapentinoid (i.e., pregabalin or gabapentin)
and any type of SNRI (i.e., duloxetine, milnacipran, or
venlafaxine) either concurrently or sequentially during the
study. Concurrent or sequential use of duloxetine and
pregabalin was reported by 227 (13.4%) patients, and 67
(3.9%) patients took milnacipran and pregabalin concur-
rently or sequentially during the course of the study.
The mean (SD) MPR for the patients in each of the four
medication cohorts on their initiated medications were
pregabalin, 0.61 (0.38); duloxetine, 0.61 (0.39); milnacip-
ran, 0.39 (0.41); and TCA, 0.56 (0.42). For the overall
sample, opioids had the highest mean MPR at 0.27 (0.41).
Among patients in the medication cohorts who had any
opioid use (36.5%), the MPR was 0.72 (0.34).
Few medication use differences were found between the
four cohorts (Table 2). Patients in the milnacipran cohort
were more likely to take opioids (46.3%) than patients in
the pregabalin (32.2%) or duloxetine (29.5%) cohort and
were likely to use opioids more (MPR 0.37 [0.45]) than the
other three cohorts (MPR: pregabalin 0.21 [0.37], dulox-
etine 0.21 [0.38], TCA 0.23 [0.39]). Patients in the TCA
cohort were less likely to take pregabalin (10.6%) and had
a lower mean MPR (0.06 [0.20]) for pregabalin than the
duloxetine (29.9%, 0.21 [0.37]).
From the observed data, the percentage of patients in
the pregabalin, duloxetine, milnacipran, and TCA cohorts
who discontinued their medication at 12 months was
47.7%, 42.4%, 35.1%, and 39.4%. The percentage of
patients in the pregabalin, duloxetine, milnacipran, and
TCA cohorts for whom it was “unknown” whether they
discontinued their medication at 12 months was 21.5%,
29.5%, 48.5%, and 34.8%, respectively. To account for
“unknown” patients, Kaplan–Meier survival analysis was
performed to estimate medication discontinuation rates.
Estimated time to drug discontinuation is presented in
Figure 2. Discontinuation was common during the first
month of treatment as well as during the first 3 months
of treatment, and this pattern was especially evident for
the milnacipran group. The estimates of 3-month (90-
day) discontinuation rates from Kaplan–Meier survival
analysis in the four medication cohorts were pregabalin,
32.2% (standard error [SE] = 3.4%); duloxetine, 31.2%
(SE = 3.1%); milnacipran, 43.7% (SE = 5.3%); and TCA,
33.2% (SE = 6.6%). At 12 months, the estimated drug
discontinuation rates based on the survival model
were pregabalin, 56.9% (SE = 3.8%); duloxetine, 54.2%
(SE = 3.6%); milnacipran, 57.1% (SE = 5.9%); and TCA,
54.9% (SE = 7.5%).
Patients could identify multiple reasons for discontinuation
(as many as applied) and were allowed to remain in the
study regardless of whether they discontinued the medi-
cation. Among those with available data, there were 287
affirmative responses; the most commonly reported
reason for discontinuation for patients in all four of the
medication cohorts was adverse events (N = 182, 63.4%),
followed by lack of efficacy (“did not help,” N = 87,
30.3%). Additional reasons included the cost of treatment
(“too costly,” N = 20, 7.0%), the patient felt better (N = 3,
1.0%), and “other” reasons (N = 43, 15.0%). Finally, in
several cases, there was no reason given (N = 13, 4.5%).
Outcome Measures
Pooling across the four medication cohorts, patients
reported statistically significant improvements in the BPI
pain severity, BPI pain interference, SDS, and FIQ from
baseline to each follow-up visit where the measure was
included throughout the 12 months (all P < 0.001 visit
compared with baseline). The mean BPI pain severity
average score and pain interference average score at
each visit for patients in the four medication cohorts are
presented in Figure 3a and b, respectively. Pairwise com-
parisons between medication cohorts revealed only one
significant overall between-group differences. Patients in
the duloxetine cohort reported a greater reduction in pain
severity compared with patients in the milnacipran cohort
(adjusted means estimate [SE] = -0.28 [0.14], P = 0.048).
No other significant differences emerged on the BPI pain
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severity measures. On the BPI interference score, there
were no significant overall differences between the
patient cohorts.
The mean FIQ total score and the mean SDS total score at
each visit for patients in the four medication cohorts is
presented in Figure 3c and d, respectively. Adjusted pair-
wise comparisons between medication cohorts revealed
no significant between-treatment differences on the FIQ or
the SDS.
Sensitivity analyses were conducted using multiple
methods. For the pairwise comparisons following the pro-
pensity score matching procedure, the number of patients
in each of the matched samples was pregabalin vs dulox-
etine, 162; duloxetine vs milnacipran, 117; and duloxetine
vs TCA, 57. There were no statistically significant differ-
ences in baseline characteristics between the cohorts
after the propensity matching procedure. Results on the
matched samples confirmed the initial findings; significantFigure 2 Time to drug discontinuation (baseline to
12 months). TCA = tricyclic antidepressant.
(a) (b)
(c) (d)
Figure 3 Mean changes from baseline to 12 months on outcome measures. BPI = Brief Pain Inventory;
FIQ = Fibromyalgia Impact Questionnaire; SDS = Sheehan Disability Scale; TCA = tricyclic antidepressant.
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differences emerged only on the BPI pain severity average
score, with patients in the duloxetine cohort reporting
greater pain reduction compared with patients in the mil-
nacipran cohort (estimate -0.35 [0.15], P = 0.026).
Economic Factors
Information on resource utilization and other economic
measures over the course of the study, for the overall
sample as well as for each of the medication cohorts, is
presented in Table 3. For the overall sample, patients
reported approximately 20 visits annually for outpatient
care (20.3 at baseline, 21.2 over 12 months). Compared
with the 12 months prior to the beginning of the study,
there were patient-reported reductions in the number of
days of missed work due to FM (27.7 to 25.0) and in the
days that patients cut down their activity by at least half
(100.7 to 86.5), yet the number of days in bed and days
patients received disability income increased (38.4 to 40.6
days; 96.6 to 98.2 days, respectively).
Pairwise comparisons using Poisson regression among
the medication cohorts revealed multiple statistically sig-
nificant differences in resource utilization (Table 3). Over
the 12-month study period, patients in the duloxetine
cohort reported fewer outpatient visits compared with
patients in the pregabalin (P = 0.005) or TCA (P = 0.003)
cohorts; likewise, patients in the milnacipran cohort
reported fewer outpatient visits than those in the pre-
gabalin (P = 0.022) or TCA (P = 0.008) cohorts. As sum-
marized in the table, there were also cohort differences
in number of days that a family member missed paid
work due to the patient’s FM as well as the number of
days that either a paid or unpaid caregiver was required.
Sensitivity analyses using the propensity matched
samples tended to show fewer statistically significant
pairwise differences than the regression analyses, in part
due to the smaller sample sizes, though results were
directionally consistent.
Satisfaction with Medical Care
Most patients rated their satisfaction with overall treat-
ment and their fibromyalgia medication as “very good” or
“excellent” (46.0% and 42.8%, respectively). The per-
centage of patients reporting a level of satisfaction (with
overall treatment and with medication) that was either
“very good” or “excellent” for each of the four medication
cohorts is presented in Figure 4. Across all study time
points, there were no statistically significant differences
between the medication cohorts in patients’ level of sat-
isfaction with their overall care. However, patients in the
pregabalin, duloxetine, and milnacipran cohorts, respec-
tively, were significantly more likely to report satisfaction
with their medication than were patients in the TCA
cohort (odds ratio [confidence interval] = 1.97 [1.12,
3.48], P = 0.018, for pregabalin; 1.83 [1.05, 3.18], P =
0.033, for duloxetine; and 1.91 [1.04, 3.50], P = 0.037,
for milnacipran).
Discussion
The REFLECTIONS study was designed to describe treat-
ment patterns and outcomes for patients with FM in a
naturalistic setting. The longitudinal study results indicate
that patients with FM used multiple pain medications over
12 months to treat their FM. Augmenting current therapy
was common, as was discontinuing from medications
early in the study period. Patients displayed some
improvements in health outcomes and function. Satisfac-
tion with overall treatment and with the current medication
was high for the majority of patients.
Longitudinal Treatment Patterns
Similar to the baseline REFLECTIONS findings [28],
treatment patterns continued to be complex over the 12
months of the study. Although patients were taking at
least one medication for FM on the vast majority of days
(98.6%), length of time on any individual drug was less
than optimal based on the standard MPR cutoff point of
0.80 for an adequate time on medication [47]. MPR
rates in the REFLECTIONS study were 0.61 for pregaba-
lin and duloxetine, 0.56 for TCAs, and 0.39 for milnacip-
ran. These MPR results are slightly lower than those
reported in retrospective insurance claims of patients
with FM in which cohorts were matched on demograph-
ics, pre-drug initiation clinical and economic characteris-
tics, and pre-drug initiation treatment patterns; results
found 12-month MPRs of 0.50 for pregabalin and 0.70
for duloxetine [25]. Similar to the baseline findings where
drugs with less evidence based on treatment guidelines
were frequently used, NSAIDs and opioids continued to
be used throughout the 12-month study [28]. Non-
adherence in the use of prescribed medications has
been previously reported to be common in FM patients
and was associated with factors such as the therapeutic
relationship between the physician and patient as well as
other psychosocial characteristics [48]. With patients ini-
tiating on 145 unique medications and averaging five
unique medications over the course of 12 months, our
study may imply that patients continue to search for
effective treatment of ongoing symptoms. Patients may
be satisfied with a medication for the short time they
take it, but they continually adjust their regimens. In this
study, reasons for discontinuation were primarily adverse
events and lack of efficacy. However, observation of
discontinuation rates reported a good portion of
“unknowns,” which should be considered in the interpre-
tation of these findings.
High rates of therapy switching, augmentation, and dis-
continuation are not unique to patients with FM. In a
recent study of patients with osteoarthritis who were
newly prescribed pain medications in a real-world setting,
90% of patients had switched, augmented, or discontin-
ued their therapies within 6 months [49]. Intolerability to
medications and suboptimal pain relief were suggested
as the primary reasons for changes in osteoarthritis
pain therapy.
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Health Outcomes
Health outcome measures of pain severity, pain interfer-
ence, disability, and the impact of FM improved through-
out the 12 months of the study. Comparisons across the
four medication cohorts found few differences across
measures of pain severity and interference with pain and
no differences in disability or the impact of FM. The
modest differences between medication cohorts may be
due to the ability of physicians to appropriately match
patients to medications because, prior to propensity
matching, there were significant differences between the
groups on factors such as race, region where treated
(Puerto Rico or United States), medication history, and
prescribing physician characteristics. From the baseline
assessment, current medication use was most strongly
associated with medication history and physician specialty
instead of clinical characteristics, where patients seen by
specialists (vs primary care) not taking opioids or NSAIDs
were more likely to be currently taking the three medica-
tions with regulatory approved indications for FM vs all
other medications [28]. Based on these findings, we
adjusted for these variables in a propensity score model to
attempt to attenuate this bias. Differences may also be
difficult to glean because of the use of concurrent medi-
cations and the high rate of discontinuation for initiated
medications over the 12 months. For example, approxi-
mately 13% of the sample was taking both pregabalin and
duloxetine at some time during the 12 months. Roughly
half of patients discontinued their initial medications
sometime during the 12 months of the REFLECTIONS
study. However, Walitt et al. [3] also reported modest
improvements in outcomes over an average of 4 years
among rheumatology patients who met American College
of Rheumatology 2010 diagnostic criteria for FM. The
current study expands the generalizability of these find-
ings; patients were enrolled from multiple physician spe-
cialties, and diagnosis was based on the enrolling
physician’s opinion. Additionally, the patients had a lower
mean pain severity score at baseline, yet modest improve-
ments were still reported.
High satisfaction was reported by study patients with their
overall care and with their medication regimens. Satisfac-
tion was highest in patients initiating on pregabalin, dulox-
etine, or milnacipran and lower in patients initiating on
TCAs. The rates of high satisfaction are somewhat incon-
sistent with modest improvements in symptom severity
and the variability in treatment patterns. Satisfaction may
depend upon increased physician interactions [50] or
patient expectations during ongoing experimenting with
therapies for the management of FM [51].
Economic Outcomes
To our knowledge, this is the first longitudinal prospective
observational study of FM patients with new drug initiation
that also assessed resource use, measures of productivity,
and caregiver burden. The current study corroborates pre-
vious retrospective claims studies finding that patients
with FM are heavy users of health care resources and that
FM is associated with lower level of work productivity
[5,23]. Overall, patients reported high annual mean rates
of outpatient visits with approximately 20 visits for outpa-
tient care. The number of outpatient visits increased over
time for all drug cohorts except for milnacipran, which had
the highest average pre-study rate of outpatient visits; this
rate generally tended to reduce over time to rates seen for
Figure 4 Percentage of patients rating their satisfaction with care as “excellent” or “very good” during the
study (baseline to 12 months). TCA = tricyclic antidepressant.
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the other drug cohorts. More intensive care measures
(number of ER visits and partial day and night care) tended
to reduce or remain at low rates or stable rates over time.
This may be an indicator that symptoms become more
manageable over time. However, reliance on others rose
over time as measured by the number of days family
members hired paid caregivers, days of unpaid or paid
caregivers, and days receiving disability payment regard-
less of the drug initiated. Being cognizant of these effects
on families may be useful as disease management pro-
grams target social support during long-term care. Vari-
ability was found across economic outcomes: initiators on
duloxetine and milnacipran (vs pregabalin or TCAs) had
fewer outpatient visits post-study. However, between-
drug comparisons of other economic indicators such as
missed work or the need for paid or unpaid caregivers
varied by drug. Continued modifications in medications
may contribute to the modest changes in the pre-study
health care use patterns compared with health care use
during the 12 months of the study. In general, patients
initiating on TCAs reported fewer declines across most of
the measures of health care resources. These findings
may be attributable to the cohort differences rather than
drug differences. TCAs are generic medications that are
relatively inexpensive, and unlike branded medications,
they are typically available on most insurance formularies
without any restrictions. There may be additional unmea-
sured confounding variables that differ between this
cohort and the other three that influence treatment selec-
tion and use of other health care resources.
Caregivers, often family members, experience consider-
able burden. In this study, patients were cared for by an
unpaid caregiver or relative on average for more than 30
days in a 12-month period. Further, during the study,
patients stayed in bed for most of the day on an average
of approximately 40 days and reported that they cut down
on daily activities on approximately 86 days, presumably
leaving family members to take care of household chores
and care for the family.
Results need to take into account the following limitations.
First, the study was not designed to assess comparative
effectiveness of specific medications. Patients were not
randomized to medication cohorts; thus selection bias
remains an issue. While regression and propensity adjust-
ment methods can account for a substantial bias due to
measured confounders, one cannot account for potential
bias due to unmeasured confounders (a standard
assumption for all observational research). Second, small
sample sizes, especially for the milnacipran and TCA
groups (both of these groups had fewer than 200 sub-
jects), limits the statistical power for cohort comparisons.
Third, while the repeated-measure methodology can
address missing data that is missing at random, if patients
dropped out of the study due to any factors not included
in the model, the overall results can be biased. Lastly,
medication cohorts were based on the newly initiated
medication, yet the majority of patients were treated with
multiple medications, and many switched or stopped the
medications during the trial, making conclusions regarding
specific effects of individual medications challenging. The
study was also conducted at a time when duloxetine and
milnacipran were newly approved for use in FM.
In conclusion, this study illustrates the health and eco-
nomic outcomes of patients with FM and describes the
use of medications in this population over time. The
strength of the study is that it was conducted in patients in
actual clinical practice with results assessed outside of the
medical office via structured CATI. This study substanti-
ates the complexity of FM treatment that is suggested by
retrospective claims studies in “real-world” patients in
clinical practice and expands the information gained from
clinical trials, from which patients with medical comorbidi-
ties or concomitant medication use are excluded. Of note
is that the study documented slight improvements in
symptoms and satisfaction with treatment in these report-
edly difficult-to-treat patients. The study documented that
most patients took combinations of prescription medica-
tions for their FM. Most patients entered the study on two
or more medications, and many patients continued use of
opioids or NSAIDs throughout the study. Future studies
might focus on whether patients with FM receive an
adequate course of therapy with appropriate dosing and
duration of monotherapy medication before advancing to
new and more complex regimens. A recent review by
Mease et al. [52] highlights the importance of future
research to examine the efficacy and safety of combina-
tion therapies for FM and to learn more about the patho-
genesis of the various symptoms associated with FM so
that therapies can be developed that adequately target
these pathogenetic pathways and symptomatic domains.
Despite the complexity of treatment and the modest
improvements seen in symptoms, patients with FM in this
study reported satisfaction with the overall care they
received and with the medications prescribed for them by
their health care providers.
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